

# PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Release of Patent Security Agreement recorded at Reel 025649/Frame 0609
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
LifeCell Corporation	07/11/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Revivacor, Inc.
<b>Street Address:</b>	1700 Kraft Drive, Suite 2400
<b>City:</b>	Blacksburg
<b>State/Country:</b>	VIRGINIA
<b>Postal Code:</b>	24060
<b>PROPERTY NUMBERS Total: 4</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	10080713
Application Number:	11641644
Patent Number:	7795493
Application Number:	11083393
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(949)475-4754
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	949-451-3800
<b>Email:</b>	skann@gibsondunn.com
<b>Correspondent Name:</b>	Stephanie S. Kann, Senior Paralegal
<b>Address Line 1:</b>	3161 Michelson Drive
<b>Address Line 2:</b>	Gibson, Dunn & Crutcher LLP
<b>Address Line 4:</b>	Irvine, CALIFORNIA 92612
<b>ATTORNEY DOCKET NUMBER:</b>	93513-00051
<b>NAME OF SUBMITTER:</b>	Stephanie S. Kann

CH \$160.00 10080713

501592288

**PATENT**  
**REEL: 026578 FRAME: 0259**

Total Attachments: 5

source=LifecellUSPTO Release#page1.tif

source=LifecellUSPTO Release#page2.tif

source=LifecellUSPTO Release#page3.tif

source=LifecellUSPTO Release#page4.tif

source=LifecellUSPTO Release#page5.tif

**RELEASE OF PATENT SECURITY AGREEMENT**

This Release of Patent Security Agreement (this "Release") is given as of July 11, 2011, by LifeCell Corporation, a Delaware corporation, with an address of One Millennium Way, Branchburg, New Jersey 08876 (the "Agent") for the benefit of Revivicor, Inc., a Delaware corporation, with an address of 1700 Kraft Drive, Suite 2400, Blacksburg, Virginia 24060 (the "Debtor");

WHEREAS, Debtor has fully discharged and satisfied the obligations secured by the Patent Security Agreement, dated as of December 22, 2010, between the Debtor and the Agent (the "Security Agreement"). The Security Agreement was recorded in the United States Patent and Trademark Office at Reel 025649/Frame 0609 against the patents attached hereto as Exhibit A (the "Patent Collateral"); and

WHEREAS, Debtor has requested that the Agent release, and the Agent is willing to release, subject to the terms hereof, its security interest, and any other right, title and interest it may have in and to the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Agent does hereby terminate and release any and all security interests it may have in and to the Patent Collateral and thereby discharge the recordation of the Security Agreement against the Patent Collateral.
2. Agent agrees to take such further action as may be reasonably requested by Debtor, from time to time, at Debtor's expense, to effectuate and carry out the provision and intent of this Release.
3. Agent represents and warrants to Debtor that it has not conveyed, transferred, granted a security interest in, hypothecated or otherwise pledged or disposed of any of the rights, title or interest granted to the Patent Collateral under the Security Agreement to any party other than Debtor.

EXECUTION COPY

IN WITNESS WHEREOF, the undersigned has caused this Release of Security Agreement to be executed and delivered as of the date first written above.

LIFECELL CORPORATION

By:  \_\_\_\_\_

Name: Adam Rodriguez

Title: VP, Business Development & Planning

Signature Page to Release of Patent Security Agreement

**EXHIBIT A**  
**to**  
**RELEASE OF SECURITY AGREEMENT**

**PATENT APPLICATIONS/REGISTRATION**

<b>Title</b>	<b>Application/Registration Number</b>	<b>Country</b>
Genetic Modification of Somatic Cells and Uses Thereof	AU 2008202720 (Div2)	Australia
Genetic Modification of Somatic Cells and Uses Thereof	AU 29267/00	Australia
Genetic Modification of Somatic Cells and Uses Thereof	CA 2,361,943	Canada
Genetic Modification of Somatic Cells and Uses Thereof	EP 00907792.6	Europe
Genetic Modification of Somatic Cells and Uses Thereof	JP 2000-601905	Japan
Genetic Modification of Somatic Cells and Uses Thereof	NZ 514620	New Zealand
Genetic Modification of Somatic Cells and Uses Thereof	NZ 530425	New Zealand
Method of Preparing a Somatic Cell for Nuclear Transfer	10/080,713	U.S.
Method of Preparing a Somatic Cell for Nuclear Transfer	11/641,644	U.S.
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3	7,795,493	U.S.

Galactosyltransferase		
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	AU 2003295322	Australia
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	CA 2,496,761	Canada
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	EP 03786504.5	Europe
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	JP 2004-539849	Japan
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	NZ 538464	New Zealand
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	NZ 562736 (DIV)	New Zealand
Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase	NZ 576646 (Div2)	New Zealand
Tissue Products Derived from Porcine Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	11/083,393	U.S.
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	AU 2005223617	Australia

Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	CA 2,559,720	Canada
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	CN 200580015470.4	China
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	EP 05732639.9	Europe
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	HK 07103852.4	Hong Kong
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	JP 2007-504086	Japan
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	KR 10-2006-7021553	Korea
Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase	NZ 549953	New Zealand